X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Recommendation of “Moderate Buy” from Analysts

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) has earned an average rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.25.

A number of analysts have recently weighed in on the company. Leerink Partners started coverage on X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price for the company. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They set an “overweight” rating and a $11.00 price objective on the stock. Finally, Weiss Ratings raised shares of X4 Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 25th.

Insider Buying and Selling

In related news, CFO David Kirske sold 8,543 shares of the business’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the transaction, the chief financial officer owned 167,750 shares in the company, valued at approximately $714,615. The trade was a 4.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, President John Volpone sold 24,576 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total transaction of $109,117.44. Following the completion of the sale, the president owned 265,305 shares of the company’s stock, valued at approximately $1,177,954.20. This represents a 8.48% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 80,555 shares of company stock valued at $356,126 over the last ninety days. Insiders own 1.13% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers lifted its stake in X4 Pharmaceuticals by 5.4% in the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after acquiring an additional 9,690 shares in the last quarter. SummitTX Capital L.P. bought a new position in shares of X4 Pharmaceuticals during the 1st quarter worth approximately $46,000. Pettinga Financial Advisors LLC bought a new position in shares of X4 Pharmaceuticals during the 2nd quarter worth approximately $47,000. Two Sigma Investments LP acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $47,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of X4 Pharmaceuticals in the fourth quarter valued at approximately $50,000. 72.03% of the stock is owned by institutional investors.

X4 Pharmaceuticals Stock Up 2.9%

Shares of XFOR opened at $3.50 on Friday. The stock has a market cap of $347.02 million, a price-to-earnings ratio of -2.92 and a beta of 0.39. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. X4 Pharmaceuticals has a 12 month low of $2.80 and a 12 month high of $4.83. The company has a 50-day moving average price of $4.02 and a two-hundred day moving average price of $4.03.

X4 Pharmaceuticals (NASDAQ:XFOR) last posted its earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.05. The business had revenue of $8.81 million for the quarter, compared to analyst estimates of $2.42 million. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. Equities analysts predict that X4 Pharmaceuticals will post -0.67 EPS for the current fiscal year.

X4 Pharmaceuticals News Roundup

Here are the key news stories impacting X4 Pharmaceuticals this week:

• Positive Sentiment: Oversold conditions may support a rebound: XFOR has fallen 20.8% over the past four weeks, and Zacks says the stock is now technically oversold. The analysis suggests selling pressure may be losing momentum, while upward earnings-estimate revisions could help trigger a trend reversal. X4 Pharmaceuticals Loses 20.8% in 4 Weeks
• Positive Sentiment: Several near-term earnings forecasts improved: Brookline raised its 2026 full-year EPS estimate to a loss of $0.71 from $0.79, its 2027 estimate to a loss of $0.90 from $0.95, and its Q3 and Q4 2026 estimates to losses of $0.20 and $0.25, respectively. These revisions point to somewhat better expected profitability in the near term. Brookline Capital Markets XFOR Estimates
• Neutral Sentiment: Reported short-interest data is inconclusive: The report lists short interest at zero shares as of September 10, unchanged from the prior period, implying no measurable short-selling pressure. However, the figures appear anomalous and provide little actionable insight.
• Negative Sentiment: Long-term earnings expectations were reduced: Brookline cut its FY2028 EPS forecast to a loss of $1.29 from $0.26 and its FY2029 forecast to a loss of $0.15 from $0.99. Its FY2030 estimate also fell to $2.86 from $3.29, signaling greater uncertainty about the timing and scale of X4’s eventual profitability. Brookline Capital Markets Long-Term XFOR Estimates

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.